Berger Disease Treatment Breakthrough: What VOYXACT’s FDA Approval Means for IgA Nephropathy Patients

A silent immune malfunction has been stealing kidney function from Americans in their 20s and 30s for decades with no real treatment. That may have just changed — and the latest data is even more promising than anyone expected.

Your kidneys are quietly under attack. For roughly 200,000 Americans living with IgA nephropathy — also known as Berger disease — that is not a metaphor. The disease is characterized by the buildup of IgA in the kidneys, leading to blood in the urine, protein leakage, and over time, the progressive loss of kidney function and potential kidney failure. For decades, there was no approved therapy capable of interrupting the underlying biological process. Patients were told to manage symptoms and wait. AJMC

Now, that calculus has shifted. On November 25, 2025, the FDA granted accelerated approval to sibeprenlimab (Voyxact), a targeted therapy from Otsuka Pharmaceutical, for reducing proteinuria in adults with primary IgAN at risk of disease progression. And just weeks ago, new data released in June 2026 showed the drug may be doing something even more significant than controlling a lab marker — it may actually be preserving the kidneys themselves. HCP Live

What Is Berger Disease, and Why Has It Been So Hard to Treat?

The disease is deceptively quiet. IgA nephropathy is a progressive, immune-mediated chronic kidney disease that typically manifests in adults aged 20 to 40 years and can lead to end-stage kidney disease over the lifetime of most patients. A person in their late 20s can receive the diagnosis, be told their kidneys are slowly failing, and be handed supportive care — blood pressure medication, dietary changes — and little else. Otsuka US

The root cause is a defective antibody called galactose-deficient IgA1. The immune system recognizes it as foreign, mounts an attack, and that inflammatory response scars the kidney tissue over time. For years, management centered largely on supportive care with renin-angiotensin system blockade and, in select patients, corticosteroids — blunt instruments that address downstream inflammation but leave the initiating biological signal untouched. AJMC

An estimated 200,000 Americans are living with IgA nephropathy right now. The question no one in nephrology wanted to answer: why has it taken this long to treat the cause? [epidemiological data: peer-reviewed U.S. prevalence studies]

How Does VOYXACT Actually Work?

This is where the science becomes important — and where the drug’s approval represents a genuine departure from everything that came before it.

VOYXACT is a humanized monoclonal antibody that binds to and blocks APRIL — a protein that plays a key role in the pathogenesis of IgA nephropathy by promoting the production of the defective galactose-deficient IgA1 that drives kidney damage. In plain terms: rather than trying to mop up the consequences of that defective antibody after it deposits in kidney tissue, VOYXACT cuts off the signal that tells the immune system to make it in the first place. Otsuka US

Administration is via a prefilled syringe for subcutaneous self-injection every four weeks at home. Patients do not need to visit an infusion center. They do not require hospitalization. The treatment fits into an ordinary life in a way that most biologic therapies do not — a meaningful quality-of-life consideration for people who are, in most cases, working adults in their prime years. AJMC

“Voyxact is the first approved treatment for adults with primary IgAN at risk for disease progression that blocks the activity of APRIL. I’m encouraged by its potential to help improve the outlook for IgAN patients.” — Dr. Dana Rizk, University of Alabama at Birmingham, VISIONARY trial co-chair

What Do the Numbers Actually Tell Us?

The clinical trial data is striking, though some important caveats apply. The VISIONARY trial — the largest Phase 3 IgAN study to date — demonstrated a 54.3% placebo-adjusted reduction in 24-hour urine protein-to-creatinine ratio after 12 months. Proteinuria — protein in the urine — is the primary measurable indicator that kidneys are being damaged. Cutting that marker in half, while untreated patients worsened, is the kind of result that earns an accelerated approval designation. HCP Live

Among global patients with hematuria (blood in the urine) at baseline, 82.5% of patients receiving sibeprenlimab were negative for microscopic hematuria at Week 48 — a marker reflecting reduced glomerular injury. These were not marginal improvements. They were consistent signals across multiple indicators of disease activity in a diverse international patient population. Otsuka US

If a drug can stop the damage signal before the scar tissue sets in, could we be looking at the first real chance to protect kidneys that would otherwise be lost?

The June 2026 Data That Changes Everything

Here is where the story accelerates. When the FDA granted accelerated approval in November 2025, the agency was clear: it has not been established whether Voyxact slows kidney function decline over the long-term, and continued approval may be contingent upon verification of clinical benefit in a confirmatory trial. That caveat was reasonable. Proteinuria reduction is a surrogate endpoint — a recognized proxy for long-term kidney preservation, but not a direct measure of kidney function itself. FDA

The direct measure is called eGFR — estimated glomerular filtration rate — and it is the most reliable indicator of how well the kidneys are actually filtering blood. At 12 months, VOYXACT preserved kidney function by showing a mean eGFR change from baseline of +0.7 compared to a decline of -4.8 mL/min/1.73m² in the placebo group, representing a treatment effect of 5.5 mL/min/1.73m². These results were presented at the European Renal Association Congress in Glasgow in June 2026. Otsuka USBusiness Wire

Otsuka has initiated a rolling submission of a supplemental Biologics License Application to the FDA for VOYXACT traditional approval, based on the 24-month eGFR endpoint data. The drug is no longer just reducing a lab marker. It appears to be measurably slowing — and in some cases stabilizing — the actual loss of kidney tissue. Business Wire

What Do Supporters of This Approach Actually Believe?

Critics of accelerated approval pathways — including some within the medical research community — raise legitimate concerns. They argue that surrogate endpoints like proteinuria reduction do not always translate into clinical benefit for patients. A drug can lower protein in the urine without meaningfully extending the life or function of a kidney. There is a real history of therapies approved on surrogate endpoints that later failed to demonstrate durable outcomes in confirmatory trials. Patient advocacy groups and payers who must cover high-cost biologics have every reason to ask whether accelerated approval sometimes moves faster than the evidence.

Those concerns deserve a fair hearing. The FDA’s own language on VOYXACT explicitly acknowledges that it has not been established whether Voyxact slows kidney function decline over the long-term — a disclosure patients and prescribers should take seriously. A 24-month analysis of eGFR decline will be critical to securing full approval. FDAAJMC

But the counterargument is powerful: the June 2026 eGFR data provides exactly the kind of mechanistic signal that justifies the accelerated pathway. These findings provide clinical evidence linking upstream selective APRIL inhibition to downstream preservation of kidney function, reinforcing the drug’s ability to improve long-term outcomes. Waiting for perfect long-term data while patients in their 30s lose irreplaceable kidney tissue is not a neutral choice. It is a choice with real costs. Otsuka US

Is This the Medical Accountability Moment Patients Have Been Waiting For?

For too long, the answer to a Berger disease diagnosis was a prescription for patience. Watch and wait. Manage what you can. The disease will progress; medicine will not stop it. That framing — passive, resigned, fatalistic — may have cost patients years of kidney function that could have been protected if a root-cause therapy had existed earlier.

The real question for every nephrologist in America is this: are you offering your IgAN patients VOYXACT, or are you still waiting for the system to catch up to the science?

The VISIONARY trial demonstrated a favorable safety profile, with most adverse events being mild or moderate and resolving without treatment interruption. The drug is self-administered at home every four weeks. The eGFR data suggest it is doing what the biology predicted it should do. The FDA has cleared it. The question of whether patients will actually access it — and whether their physicians are informed and proactive enough to offer it — now falls squarely on the medical system and the individuals navigating it. Applied Clinical Trials Online

Personal responsibility in health care means being an informed patient. It means not accepting a diagnosis of inevitability when the scientific evidence no longer supports one. If you or someone you know has been diagnosed with IgA nephropathy, the conversation with your nephrologist should no longer end with “there is nothing we can do.” There is. The question is whether anyone is telling you about it.

The real question isn’t whether VOYXACT will reshape how kidney disease is treated — it’s whether the patients who need it most will know it exists before it’s too late.

Think others need to hear this? Share this article. Still have questions? Subscribe to The Town Hall News for daily coverage of health, science, and accountability. Want to make your voice count? Contact your congressional representative and ask why kidney disease research remains chronically underfunded relative to its burden on American families.

Key Questions

1. Will Medicare and private insurers move quickly enough to cover VOYXACT for the estimated 200,000 Americans living with IgA nephropathy — or will access lag years behind the approval?
2. Now that 12-month eGFR data shows measurable kidney preservation, how soon will the FDA convert VOYXACT’s accelerated approval to full traditional approval?
3. How many IgAN patients are currently being managed under the old “watch and wait” standard of care when a root-cause therapy is now available?